Shares of Tvardi Therapeutics, Inc. (TVRD) are climbing around 42 percent on Tuesday morning after the company announced results from its Phase 1 study of TTI-109, its next-generation STAT3 inhibitor, showing improved tolerability and target engagement. The company's shares are currently trading at...
Tvardi Therapeutics, Inc. (TVRD) has reported results from its Phase 1 study of TTI-109, its next-generation STAT3 inhibitor, confirming the drug's prodrug design and improved tolerability compared to its predecessor TTI-101.
Tvardi Therapeutics (TVRD) announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. The study confirmed rapid prodrug conversion, dose-proportional pharmacokinetics with exposures above the STAT3 IC50 and, in an exploratory pharmacodynamic analysis, reductions of up to 60% in STAT3-driven...
Tvardi Therapeutics, Inc. (TVRD) reported fourth-quarter and full-year 2025 financial results and highlighted progress across its STAT3-targeted pipeline, including upcoming data readouts for both its next-generation inhibitor TTI-109 and its lead candidate TTI-101.
Tvardi Therapeutics, Inc. (TVRD) collapsed 83.95% to $6.68, down $34.92, after reporting that its experimental lung drug TTI-101 showed no benefit in a Phase 2 trial for idiopathic pulmonary fibrosis - IPF. The study failed to meet its goals, with many patients discontinuing treatment due to gastrointestinal...
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.